ARS Pharmaceuticals
SPRY
Performance
About ARS Pharmaceuticals
ARS Pharmaceuticals is focused on enhancing safety for individuals at risk of severe allergic reactions through innovative solutions. They are developing ARS-1, an intranasal epinephrine spray designed for comfort and reliability, aimed at providing an easier and more effective way for patients and caregivers to manage anaphylaxis due to food, medications, and insect stings.
Recent News
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
SPRY Therapeutics Secures FDA Label Expansion for Needle‑Free Epinephrine Spray
ARS Pharma Posts $84.3M Revenue, CFO Scott Outlines Growth‑cost Balance
Trade Secret Litigation Trends in Life Sciences
Rezolute Inc (RZLT) Q3 2026 Earnings Call Transcript
William Blair Reiterates Outperform on ARS Pharma Stock After FDA Label Update
Pharvaris NV (PHVS) Q4 2025 Earnings Call Transcript
ARS Pharma Secures FDA Label Expansion for Neffy Needle‑Free Epinephrine Spray
Recent Deals
No recent deals for this company.